UK 356618|cas:230961-08-7|西域试剂

UK 356618,98.0%

产品编号：Bellancom-107394| CAS NO：230961-08-7| 分子式：C₃₄H₄₃N₃O₄| 分子量：557.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-107394	￥1700.00	杭州北京（现货）
Bellancom-107394	￥5100.00	杭州北京（现货）
Bellancom-107394	￥8700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

UK 356618

产品介绍

UK 356618 (Compound 4j) 是一种有效且选择性的基质金属蛋白酶 3 (MMP-3) 抑制剂，其 IC₅₀ 值为 5.9 nM。与 MMP-3相比，UK 356618 对 MMP-1，MMP-2，MMP-9， MMP-13 和 MMP-14 的抑制效力较低。

生物活性

UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC₅₀ of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3.

体外研究

Inhibition of MMP-3 and selectivity over MMP-2 was remarkably sensitive to the size of the substituent and is clearly optimal for a methyl group (UK 356618, compound 4j). UK 356618 is more widely profiled against other MMPs.
MMP-13 is closely involved in IL-6 or TNF-α increasing tumor metastasis. MMP-13 deficiency abrogate TNF-α effect on lung cancer cell migration. UK 356618 treatment efficiently abolished the effect of TNF-α on cell migration in NCI-H446 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

UK 356618 (15 mg/kg; intravenous injection; for 24 h or 7 days; male Wistar rats) treatment at reperfusion significantly reduces MMP3 activity in the brain.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hyperglycemic male Wistar rats injected with middle cerebral artery occlusion (MCAO)
Dosage:	15 mg/kg
Administration:	Intravenous injection; for 24 h or 7 days
Result:	Significantly reduced MMP3 activity in the brain.

体内研究

UK 356618 (15 mg/kg; intravenous injection; for 24 h or 7 days; male Wistar rats) treatment at reperfusion significantly reduces MMP3 activity in the brain.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hyperglycemic male Wistar rats injected with middle cerebral artery occlusion (MCAO)
Dosage:	15 mg/kg
Administration:	Intravenous injection; for 24 h or 7 days
Result:	Significantly reduced MMP3 activity in the brain.

性状

Solid

溶解性数据

In Vitro:

DMSO : 25 mg/mL (44.83 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7930 mL	8.9651 mL	17.9301 mL
5 mM	0.3586 mL	1.7930 mL	3.5860 mL
10 mM	0.1793 mL	0.8965 mL	1.7930 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式